Eric Kauffman, MD

Associate Professor of Oncology
Department of Urology
Department of Cancer Genetics

Eric Kauffman, MD

Dr. Kauffman was appointed to the faculty at Roswell Park Comprehensive Cancer Center (Roswell Park) in 2012. He serves in the Department of Urology and in the Department of Cancer Genetics. Dr. Kauffman attended the Pritzker School of Medicine at the University of Chicago, IL, where he earned his medical degree (2004) and was awarded a Howard Hughes Medical Institute fellowship for molecular research in prostate cancer (2001-2002). He subsequently completed his internship in General Surgery (2006) and residency in Urology (2010) at New York Presbyterian Hospital of Weill Medical College, Cornell University in New York, NY. He completed a clinical and research fellowship in Urologic Oncology at the National Cancer Institute of the National Institutes of Health in Bethesda, MD in 2012. 

Dr. Kauffman specializes in the care of patients with kidney and prostate cancers and provides expertise in both robot-assisted and open operative approaches, including partial or radical nephrectomy and radical prostatectomy. His research interests include active surveillance as a primary management option for patients with low-risk kidney cancers, and the molecular characterization of early metastatic potential in kidney and prostate cancers, including molecular marker discovery and elucidation of signaling pathways for therapeutic targeting. 

Dr. Kauffman is a member of the American Urological Association and the Society of Urologic Oncology. 

Dr. Kauffman has authored and co-authored several peer-reviewed publications, book chapters and abstracts on genitourinary oncology topics.


Related Videos

VHL Syndrome Q&A with Roswell Park Comprehensive Cancer Center Video

VHL Syndrome Q&A with Roswell Park Comprehensive Cancer Center

VHL (von Hippel-Lindau disease) is a rare genetic disease that can cause tumors, both benign and malignant, to develop in up to ten different organs throughout a patient's life.

Expanding Active Surveillance for Kidney Cancer – Insights from the Highest Active Surveillance Site in the United States Video

Expanding Active Surveillance for Kidney Cancer – Insights from the Highest Active Surveillance Site in the United States

Surgery has long been the gold standard for treatment of kidney cancer. However, for small kidney cancer, surgery is not always necessary and may cause complications for some patients.Roswell Park Comprehensive Cancer Center has been at ...